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Periplakin is a member of the plakin family of cytolinkers that connect cytoskeletal networks to each other as well
as to the cell junctional complexes. Here, we demonstrate a direct molecular interaction between actin and pe-
riplakin. Furthermore, the oligomerization state of periplakin was shown to determine speciﬁcity of its binding to
intermediate ﬁlaments (IF) in vitro. Both the ﬁlament association and the cell membrane localization of periplakin
were conﬁrmed in the cells overexpressing human periplakin. Double labeling of the N- and C-terminally tagged
periplakin revealed unexpected lack of co-localization of periplakin ends in a conﬂuent culture, and separation of
the periplakin ends was even more pronounced in apoptotic cells. Western analysis revealed that after induction of
apoptosis, periplakin becomes cleaved close to its C-terminal tail. Only the distinct cleavage products, but not the
full-length periplakin, were present in the cells detached from the solid support during the apoptotic process. We
show that caspase 6 cleaves periplakin at an unconventional recognition site, amino acid sequence TVAD. Thus,
the separation of periplakin ends disconnects the actin-binding head-rod domain from the IF-binding C-terminal
domain. We show that specific cleavage products co-exist with the full-length periplakin in cells, suggesting
physiological consequences due to their altered binding speciﬁcities.
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Periplakin is one of the five plakin proteins that share a
common structure of a central rod domain flanked by N-
and C-terminal globular domains; the other members of this
family of proteins are desmoplakin, plectin, envoplakin, and
the 230-kDa bullous pemphigoid antigen (BPAG1) (for re-
views, see Ruhrberg and Watt, 1997; Fuchs and Yang,
1999; Leung et al, 2001a; Leung et al, 2002; Huber, 2003).
The central rod domain is composed of heptad repeats
potentially forming a coiled-coil structure that assembles
plakin polypeptides into parallel homo- or heterodimers
(Kalinin et al, 2004). The N-terminal domain displays highest
structural homology between five plakin proteins. Function-
ally, the head domain of desmoplakin is involved in binding
to the desmosomal plaque proteins (Bornslaeger et al,
1996) and it also binds to actin (Huen et al, 2002). Alterna-
tive splicing of exons encoding the actin-binding domain
generates specific isoforms of BPAG1 (Leung et al, 2001b)
and plectin (Fuchs et al, 1999; Andra¨ et al, 2003; Garcia-
Alvarez et al, 2003), with unique binding properties to actin
microfilaments. Plectin also binds a6b4 integrin through its
N-terminal domain (Rezniczek et al, 1998; Geerts et al,
1999; Litjens et al, 2003). Periplakin has been demonstrated
to co-localize with cortical actin at the plasma membrane of
cultured keratinocytes (DiColandrea et al, 2000). On the
other hand, the ability to bind intermediate filaments (IF)
through the C-terminal region is shared among plakins (Le-
ung et al, 2002; Huber, 2003). The length of the C-terminal
globular domain varies from about 2000 residues in plectin
to just 111 residues in periplakin. Although IF binding is
mediated through this C-terminal region, the adjacent rod
domain may also contain sequences critical for these inter-
actions (Stappenbeck and Green, 1992; Nikolic et al, 1996;
DiColandrea et al, 2000; Choi et al, 2002; Karashima and
Watt, 2002; Kazerounian et al, 2002; van den Heuvel et al,
2002; Fontao et al, 2003). The ability to bind actin micro-
filaments via its N-terminal domain and to provide a con-
nection to the IF via the C-terminal domain has designated
plectin as a prototype molecule of these versatile cytolin-
kers (Steinbo¨ck and Wiche, 1999). Periplakin, although
smaller than plectin, also emerges as a potential cytolinker.
Periplakin was originally identified as a precursor of the
cornified cell envelope in terminally differentiated epidermal
keratinocytes (Simon and Green, 1984; Ma and Sun, 1986;
Ruhrberg et al, 1997), but its expression has also been
demonstrated in other tissues with prominent epithelial
component (Aho et al, 1998; Kazerounian et al, 2002). Un-
Abbreviations: BSA, bovine serum albumin; IF, intermediate fila-
ments; IIF, immunofluorescence; FLAG, synthetic epitope tag; HA,
epitope tag derived from influenza virus hemagglutin protein;
MDCK, Madin–Darby canine kidney; PVDF, polyvinylidene fluoride;
RT, room temperature; SDS-PAGE, sodium dodecyl sulfate-polya-
crylamide gel electrophoresis single letter code for amino acid
residues: T, threonine; V, valine; A, alanine; D, aspartic acid
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expected protein–protein interactions, identified through the
yeast two-hybrid screening, indicate novel functions for
periplakin (Aho and Kazerounian, 2003). Such periplakin
interaction partners include the intracellular domain of the
hemidesmosomal transmembrane protein-type XVII colla-
gen/BPAG2/BP180 (Aho et al, 1998; Aho, 2004a), a G-pro-
tein receptor in the brain (Feng et al, 2003), protein kinase B/
c-Akt involved in regulation of apoptosis (van den
Heuvel et al, 2002), the mannose-6-phosphate receptor
(MPR300) involved in intracellular protein trafficking (Storch,
1999), and the high-affinity immunoglobulin G (IgG) receptor
FcgRI in myeloid cells, enhancing its capacity to bind, in-
ternalize, and present antigens on major histocombatibility
complex II (Beekman et al, 2004a,b). The yeast two-hybrid
screening for periplakin interaction partners also identified a
novel protein, periphilin, which is present at cell membranes
in terminally differentiated keratinocytes (Kazerounian and
Aho, 2003). In addition, this technology has confirmed a
specific binding of periplakin to keratin 8 and vimentin
(Kazerounian et al, 2002; van den Heuvel et al, 2002). Based
on the established tissue distribution and the subcellular
localization of periplakin, the physiological relevance of the
two-hybrid interactions has remained unclear. A novel
monoclonal antibody recognizing an epitope close to the
C-terminal end of periplakin rod domain, however, revealed
an unexpected subcellular localization and tissue distribu-
tion pattern for this protein (Aho, 2004a). An increasing
number of protein–protein interactions suggests that pe-
riplakin C-terminus may be masked and not accessible for
the C-terminus-specific antibodies, which are widely used
for detection of periplakin. There is also a possibility that
due to proteolytic processing, certain protein domains are
not present in cells and tissues.
Caspases are aspartate-specific cysteine proteases that
become activated and cleave cellular proteins, mediating
elimination of damaged cells during apoptosis and contrib-
uting to programmed cell death during development
(Jacobson et al, 1997; Nicholson, 1999; Zeuner et al,
1999; Adams, 2003; Lawen, 2003; Schwerk and Schulze-
Osthoff, 2003). Characteristic morphological changes
during apoptosis are due to the cleavage of intracellular
proteins, especially those responsible for the cell–cell or
cell–matrix adhesion, as well as the integrity of the nuclear
membrane and the IF network. Desmosomal proteins, in-
cluding desmoplakin, are coordinately cleaved during
apoptosis primarily through the action of caspase 3 (We-
iske et al, 2001), whereas plectin has been reported to
function as an early substrate for caspase 8 (Stegh et al,
2000; Beil et al, 2002). Destruction of the nuclear lamina and
the collapse of the nucleus are mediated through caspase 6
cleavage of nuclear lamins (Orth et al, 1996; Ruchaud et al,
2002). Caspase 6 is also responsible for cleavage of keratin
18 (Caulin et al, 1997), keratins 15 and 17 (Badock et al,
2001), vimentin (Byun et al, 2001), and desmin (Chen et al,
2003), thus systematically targeting the IF network during
apoptosis. We recently reported that in HaCaT keratin-
ocytes, periplakin is coordinately cleaved with other plakin
proteins, and in vitro periplakin is preferentially cleaved by
caspase 6 (Aho, 2004a,b).
The specific cleavage of periplakin and the cleavage
products present in cells and tissues have not been ad-
dressed previously. Because both the full-length periplakin
and its N- and C-terminal cleavage products may simulta-
neously be present in the cells and tissues, the appearance
of periplakin signal is dependent on the tools and methods
used for their detection. Here, we provide evidence of direct
selective interaction of periplakin C-terminus with individual
IF proteins and assembled IF, as well as show direct mo-
lecular interaction between filamentous actin and periplakin
head and rod domains in vitro. We use N- and C-terminally
tagged periplakin to demonstrate that cleavage of peripl-
akin by caspase 6 produces two fragments, selectively
abolishing protein–protein interactions, and resulting in the
separation of the terminal domains in living cells.
Results
Specific interaction of periplakin with IF proteins Previ-
ous studies have described filamentous distribution for pe-
riplakin C-terminal domain in epithelial cells transfected with
various expression constructs (DiColandrea et al, 2000;
Karashima and Watt, 2002; Kazerounian et al, 2002), and
direct interaction with IF extracted from cultured cells has
also been reported (Karashima and Watt, 2002). We and
others (Kazerounian et al, 2002; van den Heuvel et al, 2002)
also demonstrated in yeast two-hybrid assay a specific in-
teraction of periplakin C-terminal domain with keratin 8 and
vimentin. As there are many more individual IF proteins (for
a review, see Parry and Steinert, 1999), which are specif-
ically expressed in cells and tissues where periplakin is
known to be abundant, it was of interest to investigate the
capability of periplakin to bind to other IF proteins as well.
The capacity of full-length periplakin or its C-terminal
fragments (Fig 1) to bind bacterially expressed purified in-
dividual IF proteins (Fig 2a) was analyzed by the dot-blot
overlay assay (Fig 2b). Full-length periplakin exhibited
strong binding to keratins 8 and 14 (Fig 2b, panel P). Weak-
er binding was also observed with vimentin and keratins 1
and 5. Although periplakin C-terminal fragment, containing
both the C-terminal third of the rod and the entire tail do-
main (Fig 2b, panel Pr231t), showed similar binding pattern
as the full-length periplakin, further shortening of the rod
domain (Fig 2b, panel Pr89t) largely abolished the binding to
Figure1
Periplakin constructs. Periplakin constructs used in in vitro binding
assays. Periplakin amino acid residues encoded by each construct are
indicated, and the ability of each domain to bind intermediate filaments
(IF) and F-actin (further detailed in Figs 2 and 4, respectively) is sum-
marized on the right.
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keratin 8 and vimentin. Accordingly, the periplakin tail do-
main alone (Fig 2b, panel Pt) was not able to bind to keratin
8 or vimentin.
Co-sedimentation assays, measuring the ability of pe-
riplakin and its domains to bind to IF, confirmed that the
periplakin tail domain is necessary but not sufficient to bind
IF assembled from keratins 8 and 18. On the one hand,
proteins Prt and Pr231t, but not corresponding fragments Pr
and Pr231 without the tail domain, were detected in the
pellet fraction after the incubation with the IF (Fig 2c, panels
Prt and Pr231t vs panels Pr and Pr231). On the other hand,
constructs containing the tail domain, preceded by just 89
residues of the rod domain, or the tail domain alone did not
show significant binding (Fig 2c, panel Pr89t, and data not
shown). In addition, the periplakin head domain did not bind
the IF (Fig 2c, panel Ph). Similar results were obtained when
vimentin IF were used in the co-sedimentation assay, ex-
cept that the binding capacity of vimentin IF for periplakin
was somewhat lower than that of keratin 8/18 IF (data not
shown). In case of keratin 8/18 IF, binding was saturated at
a stoichiometry of one Pr231t polypeptide chain per keratin
tetramer as calculated from Scatchard analysis. The Kd,
estimated from these binding data, is 2.11 mM (Fig 2d).
Surprisingly, in contrast to the overlay assay that demon-
strated a rather strong interaction between periplakin C-
terminal fragments with individual keratin 14, the co-sedi-
mentation experiments failed to demonstrate any significant
binding to IF assembled from keratins 5 and 14 (Fig 2e, and
data not shown).
Differences in IF-binding properties between constructs
Pr231t and Pr89t could be due to their different oligomeric
state. To address this possibility, we used cross-linking ex-
periments and size exclusion chromatography (Fig 3). On
the one hand, the major product of chemical cross-linking of
Pr231t was an oligomer with an apparent molecular mass of
about 140 kDa as estimated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (Fig 3a,
panel Pr231t), whereas the majority of Pr89t remained in its
monomeric form (Fig 3a, panel Pr89t). On the other hand,
the molecular mass of Pr89t was estimated as 28 kDa by
size exclusion chromatography (Fig 3b), which is reasonably
close to 23.4 kDa calculated from its amino acid sequence.
On the same column, Pr231t appeared as a molecule with
an apparent mass of about 230 kDa, which is several fold
higher than 41.6 kDa calculated for its monomer. We
Figure 2
C-terminal region of periplakin is responsible
for selective binding to intermediate fila-
ments (IF). (a) Coomassie Blue-stained gel
showing purified IF proteins, which were used
in the dot-blot overlay assay (b) and co-sedi-
mentation studies (c–e). (b) IF proteins (1 mg
each) were immobilized on polyvinylidene fluo-
ride membrane, which was probed with purified
periplakin fragments indicated on the left. Bound
periplakin was detected by antibodies as de-
scribed in Materials and Methods. No periplakin
was added in the control experiment. Equal
loading of IF proteins was verified by Amido
Black staining of the membrane. (c) The full-
length periplakin or its deletion constructs, as
indicated on the top of each panel, were incu-
bated with or without IF assembled from keratins
8 and 18 (K8 and K18). Supernatants (s) and
pellets (p) after ultracentrifugation were analyzed
by gel electrophoresis. The arrowhead marks the
position of each protein tested for binding. (d)
Quantitative analysis of Pr231t binding to K8/18
IF. Amount of protein bound to the IF was deter-
mined by densitometry of the Coomassie Blue-
stained gels. Results of three independent
experiments are shown. Error bars represent
standard deviation. (e) Co-sedimentation assay
with IF assembled from K5 and K14.
Figure3
Substantial part of the rod domain is required for oligomerization
of the periplakin in vitro. (a) Purified recombinant proteins were
chemically cross-linked (lanes ‘‘þ ’’) before separation through sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and Coomassie
Blue staining. Control samples were incubated without cross-linker
(lanes ‘‘’’). Positions of molecular mass standards (kDa) are indicated
on the left. (b) Apparent molecular mass of the recombinant proteins
(open circles) was estimated by size exclusion chromatography.
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conclude that Pr231t is forming oligomeric complexes, per-
haps as a result of lateral association of rod domain se-
quences present only in the Pr231t protein.
The subcellular distribution of periplakin was studied in
cultured cells using double labeling for the N- and C-termi-
nal tags (Fig 5a, b). In sparse cultures, where cells are well
spread and take a large surface area, the signals co-local-
ized and were detected in the cytoplasm in a filamentous
pattern. This result supports the association of periplakin
with IF, especially in non-confluent cells, which have not yet
established strong cell–cell adhesion. The filamentous pat-
tern is in agreement with the previously reported IF asso-
ciation of overexpressed periplakin (DiColandrea et al,
2000; Karashima and Watt, 2002; Kazerounian et al, 2002).
Direct molecular interaction between periplakin and F-
actin Although periplakin has been shown to co-localize
and co-distribute with cortical actin (DiColandrea et al,
2000), the possibility of direct molecular interaction of pe-
riplakin with filamentous actin has not been explored.
Therefore, the actin-binding activity of each periplakin frag-
ment was assessed through co-sedimentation with F-actin.
Full-length recombinant periplakin exhibited weak but de-
tectable affinity to actin filaments in vitro (Fig 4a). The N-
terminal head domain showed similar binding properties,
whereas the periplakin rod domain, surprisingly, showed
even stronger binding to F-actin. None of the C-terminal
periplakin fragments showed co-sedimentation with actin
(Fig 4a, panel Pr231t, and data not shown). When a range of
protein concentrations was used to determine the actin-
binding parameters, an apparent Kd of about 6 mM was
obtained for Ph (Fig 4b). This value is several fold higher
than dissociation constants estimated for actin-binding do-
mains of other plakins: BPAG1 (Kd¼0.21 mM) (Yang et al,
1996) and microtubule-actin cross-linking factor (MACF)
(Kd¼0.35 mM) (Karakesisoglou et al, 2000). Therefore, bind-
ing of Ph to actin can be described as weak, although spe-
cific. On the other hand, binding saturation for Pr was not
obtained even at concentrations as high as 8 mM, indicating
a stronger but unspecific character of the binding (Fig 4c).
In Madin–Darby canine kidney (MDCK) cells grown to
confluency, the double-tagged periplakin appeared at the
periphery of the cells along the cell–cell junctions (Fig 5c),
which is in contrast to the filamentous appearance seen in
sparse cultures (Fig 5b). The staining pattern in the conflu-
ent culture suggests co-localization of periplakin with cor-
tical actin as was shown previously (DiColandrea et al,
2000). Furthermore, in some cells FLAG-tag signal was
barely detectable, whereas a much brighter HA-tag signal
was seen as diffuse cytoplasmic staining.
Induction of apoptosis results in separation of peripl-
akin termini The surprising lack of co-localization of the
two signals in confluent cultures could be either due to
epitope masking, as was suggested previously (Aho,
2004a), or a result of a proteolytic cleavage of periplakin.
We recently found that caspase 6 cleaves periplakin in vitro
(Aho, 2004a), and in HaCaT keratinocytes after induction of
apoptosis, the endogenous periplakin is cleaved coordi-
nately with other plakin proteins (Aho, 2004b). To track the
fate of periplakin ends in apoptotic cells, we again used
MDCK cells expressing double-tagged periplakin and mon-
itored both tags through immunofluorescence (IIF) staining.
After induction of apoptosis by staurosporine (STS), shrink-
age of the cells was detectable after 1-h treatment (data not
shown) and after 3-h treatment diamidinophenyl indole
(DAPI) staining revealed prominent DNA condensation and
nuclear fragmentation (Fig 5d). In apoptotic cells, the signals
of FLAG- and HA-tags did not co-localize. The N-terminal
end of periplakin was detected mainly in aggregates,
whereas the C-terminal end appeared in the cytoplasmic
staining pattern, indicating the separation of the two ends
in the remaining adherent cells and cell debris. Periplakin
cleavage might also occur during cell/culture maturation,
thus explaining the separation of the two signals observed
in confluent cultures (Fig 5c).
Figure4
The head and rod domains of periplakin bind to filamentous actin.
(a) F-actin co-sedimentation assay was performed in a manner similar
to intermediate filament-binding experiments. The arrowhead marks
the position of each protein tested for binding. For the actin binding, a
positive (a-actinin) and negative (bovine serum albumin (BSA)) controls
are shown. (b and c) Quantitative analysis of Ph and Pr domains binding
to F-actin, respectively. Results of three independent experiments are
shown. Error bars represent standard deviation. Note saturation of
binding with increasing concentrations of Ph and absence of the sat-
uration in case of Pr.
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The examination of cell cultures revealed that after STS
addition, cells became rounded, lost their contact with the
matrix, and were gradually released into the culture medi-
um. Western analysis was used to further examine the fate
of periplakin and its fragments both in adherent and de-
tached cells (Fig 6). In adherent cells, a small amount of the
N-terminal cleavage product, corresponding to the head-
rod domain of periplakin (Fig 6), was present even in the
vehicle-treated cells (0-time). Significant increase of both
the N- and the C-terminal cleavage products was detected
in a time-dependent manner after addition of STS, although
the full-length periplakin constituted the major fraction of
periplakin in adherent cells even at 3-h time point. Signif-
icantly, only the cleavage products, but not the full-length
periplakin, were present in the detached cells. Based on the
intensity of actin signal (Fig 6, right panel), the inhibition of
caspase activity by zVAD-fmk (Biomol, Plymouth Meeting,
Pennsylvania) greatly reduced the number of detached
cells. Moreover, the caspase inhibitor almost quantitatively
eliminated the periplakin cleavage product from the adher-
ent cells, suggesting the presence of some caspase activity
in these cells already before STS treatment.
As we showed earlier, the periplakin could serve as a
substrate for caspase 6 in vitro (Aho, 2004a). Therefore, the
experiment was repeated using a caspase 6-specific inhib-
itor zVEID-fmk (data not shown). This inhibitor clearly re-
duced apoptosis and prevented periplakin cleavage in
adherent cells, although it did not completely prevent cells
from detaching, and in the floating cell pool we detected
both full-length periplakin and the cleavage fragments, sug-
gesting that the cleavage of overexpressed periplakin is not
a prerequisite for the loss of adhesion of MDCK cells. These
results also indicate that there may be other caspases, be-
sides caspase 6, cleaving periplakin.
Caspase 6 cleaves periplakin at an unconventional
cleavage site Recombinant caspases 1–10 were tested
in vitro for their ability to produce distinct fragments from
the tagged periplakin in the MDCK cell extract (Fig 7), and
caspase 14 was tested on the full-length recombinant pe-
riplakin (Kalinin, unpublished). Only caspase 6 cleaved
periplakin, producing a fragment of about 180 kDa.
Furthermore, the HA-tag-specific antibody revealed a dis-
tinct fragment, approximately 15–20 kDa in size, similar to
the periplakin cleavage product, described in Fig 6. These
results confirmed the previous work, where the utilization of
glutathione S-transferase-fusion proteins narrowed the ca-
spase cleavage site to aa 1584–1645 (Aho, 2004a). This
Figure 5
Subcellular distribution of periplakin depends
on the physiological state of the cells. (a) A
construct, encoding double-tagged periplakin
with an N-terminal FLAG- and a C-terminal HA-
epitope tag, was expressed in Madin–Darby ca-
nine kidney (MDCK) cells. In addition to the
tag-specific antibodies, periplakin is recognized
by the monoclonal antibody PPL-488, specific for
aa 1548–1583. Periplakin domains responsible
for F-actin and intermediate filament (IF) binding,
and the caspase 6 cleavage site are indicated.
N-terminally FLAG-tagged and C-terminally HA-
tagged periplakin overexpressed in MDCK cells
was double-labeled with antibodies against the
FLAG-epitope (red) and the HA-epitope (green),
and the nuclei were visualized through diami-
dinophenyl indole (DAPI) staining (blue). (b) The
filamentous staining pattern of both tags in
growing cells suggests IF association for full-
length periplakin (arrow). (c) In confluent cultures,
periplakin localized along the cell plasma mem-
brane (arrow). An unexpected lack of co-locali-
zation of the signals is evident in some cells. (d)
Separation of periplakin domains after induc-
tion of apoptosis. Distinct aggregates of the
N-terminal part of the periplakin were detected
through the FLAG-tag signal, especially in the
cells with fragmented or condensed nuclei, but
these aggregates did not stain with the HA-tag
antibody (arrows). Another type of staining,
where the FLAG-tag antibody gave a dim signal
and the HA-tag antibody was seen throughout
the cytoplasm, is indicated by the arrowheads. In
an occasional cell both signals co-localized, ei-
ther throughout the cytoplasm (encircled with a
solid line), or as prominent aggregates (encircled
with a broken line). Scale bar: 25 mm.
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region contains eight aspartate residues, potentially serving
as caspase cleavage sites. Therefore, a recombinant pe-
riplakin fragment, containing the last third of the rod and the
tail domain (Pr231t, see Fig 1), was used to determine the
caspase 6 cleavage site.
Caspase 6 cleaved the recombinant protein into two
fragments (Fig 8a, lane 2), the smaller of which showed
electrophoretic mobility identical to the C-terminal fragment
cleaved off the full-length recombinant periplakin by the
caspase 6. After transfer to polyvinylidene fluoride (PVDF)
membrane, the corresponding band was cut out and sub-
jected to N-terminal amino acid sequencing. The sequence
SGTNHD matched with periplakin amino acid residues from
1604 to 1609, and is preceded by an aspartic acid residue in
position 1603. The recognition amino acid sequence, TVAD,
although unconventional for caspase 6, is located in the
middle of a potential loop that connects the last two heptad
repeats of the periplakin rod domain (Fig 8b).
The caspase 6-generated C-terminal fragment was pu-
rified (Fig 8a, line 3) and used for IF binding experiments
along with other periplakin constructs (detailed in Fig 2). It
exhibited binding properties similar to periplakin tail (Pt)
alone (data not shown).
Discussion
In this study, we demonstrate the direct molecular interac-
tion between actin and periplakin. We also show that
oligomerization of periplakin is required for its efficient direct
binding to both vimentin and keratin 8, as well as to vimentin
and keratin 8/18 IF. Moreover, caspase 6-mediated cleav-
age of the periplakin at the end of its rod domain is ex-
pected to release the remaining N-terminal part of the
molecule from IF while retaining the ability of the cleaved tail
to interact with keratin 14.
It should be noted that we found differences in the ability
of periplakin to bind individual IF proteins in the overlay
assay versus assembled IF in the co-sedimentation assay.
In particular, periplakin was able to interact with simple IF
proteins (vimentin and keratin 8) in both their forms, where-
as interaction with keratin 14, which is expressed
in stratified epithelia, was detected only in the case of
the monomeric protein. On the contrary, desmoplakin was
shown to interact with polymerized IF proteins but not with
their monomers (Fontao et al, 2003), involving recognition
sites located primarily in the rod domain of keratins. The
authors speculated that the interaction was affected by the
tertiary structure induced by heterodimerization of IF pro-
teins. By contrast, recognition site(s) for the periplakin on
keratin 14 might be located in the keratin head or tail do-
main. Also, it has been shown that desmosomal proteins
associate predominantly with type II epidermal keratins
(Kouklis et al, 1994; Meng et al, 1997), whereas hem-
idesmosomal proteins interact with type I keratins (Aho
and Uitto, 1999; Geerts et al, 1999). Our data show that
Figure 6
Caspase-dependent cleavage of periplakin after induction of
apoptosis. Madin–Darby canine kidney cells expressing tagged pe-
riplakin were grown to 80% confluency, and 1 mM staurosporine (STS)
was applied for 1, 2, or 3 h. A caspase inhibitor zVAD-fmk (40 mM) was
added to the culture medium 30 min prior to incubation with STS. The
cleavage of periplakin was detectable at 2- and 3-h time points after
STS addition (panels a, b, c: arrows in a and b), but the preincubation
with caspase inhibitor prevented the appearance of STS-mediated
cleavage products. Actin (d) is shown as an indicator of cell count,
which significantly increased in the culture medium after induction of
apoptosis.
Figure 7
Periplakin is specifically cleaved by caspase 6 in vitro. Madin–Dar-
by canine kidney cell lysate containing tagged periplakin was subjected
to digestion with recombinant caspases 1–10 (lanes 1–10, respective-
ly). Lane 0 represents cell lysate incubated without caspase enzyme.
The caspase digests were separated by sodium dodecyl sulfate-po-
lyacrylamide gel electrophoresis and immunoblotted with mAb PPL-
488 (a) and anti-HA-tag antibody (b). The antibody PPL-488 revealed a
180-kDa cleavage product, and the HA-tag antibody demonstrated the
appearance of a short C-terminal cleavage product of 15–20 kDa in the
caspase 6-treated sample.
Figure8
Determination of caspase 6 cleavage site. (a) Purified recombinant
protein Pr231t (lane 1) was cleaved by caspase 6 into two fragments
(lane 2). His-tagged C-terminal fragment (lane 3) was purified. (b) Amino
acid residues identified by N-terminal sequencing of the cleaved His-
tagged fragment are indicated in bold and the caspase recognition site
is boxed, and the cleavage site is indicated by an arrowhead. The
heptad repeat regions in periplakin are underlined.
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periplakin can interact with both keratin 8 (type II) and
keratin 14 (type I).
Although several studies have revealed multiple interac-
tions for the periplakin C-terminal region, the molecular in-
teractions of the N-terminal domain have been studied less
extensively. Although the actin-binding calponin homology
repeats are not present in the periplakin N-terminus, the Y-
domain of periplakin shows considerable homology to
spectrin repeats, potentially mediating the specific bind-
ing of periplakin head domain to filamentous actin. Co-
localization with cortical actin even after depolymeriza-
tion of F-actin suggests either the direct or indirect
interaction between these molecules (DiColandrea et al,
2000). Our results indicate direct binding of periplakin to
actin filaments.
Taking into consideration the ability of periplakin to bind
both IF and microfilaments, it is worth noting that periplakin
seems to exhibit a preference for either one or the other
depending on cell type and/or the physiological state of the
cells. For example, full-length periplakin shows character-
istic IF staining in simple epithelial (COS7) cells (Di-
Colandrea et al, 2000; Karashima and Watt, 2002), but it
has membrane localization in keratinocytes (Ma and Sun,
1986; Ruhrberg et al, 1997; DiColandrea et al, 2000), al-
though overexpression of periplakin can lead to its redis-
tribution to IF in keratinocytes as well (DiColandrea et al,
2000). In our studies, in sparse cultures of kidney (MDCK)
epithelial cells, overexpressed periplakin showed filament-
ous cytoplasmic distribution, suggestive of co-localization
with IF, whereas in confluent cultures periplakin staining was
concentrated at the cell plasma membrane region. As
shown in this work, differences in periplakin-binding ability
to keratin 8/18 and vimentin IF, compared with K5/14 IF, can
shed light on how periplakin subcellular localization is reg-
ulated. Besides, caspase-mediated cleavage of periplakin,
disconnecting its IF-binding tail from the rest of the mole-
cule, might mediate its redistribution from IF to the plasma
membrane in maturing cultures or in terminally differentiat-
ing keratinocytes, as was shown for confluent cultures of
MDCK cells in this work.
Among caspases 1–10 and 14, only caspase 6 cleaved
periplakin in vitro. Prevention of the cleavage by specific
caspase 6 inhibitor in vivo strongly supports the role of ca-
spase 6 in the cleavage of the periplakin, although involve-
ment of other caspases besides those tested here cannot
be ruled out. Caspase 6 cleaved human periplakin at an
unconventional sequence TVAD, which is located in the
middle of a potential loop, connecting the last two heptad
repeat regions of the periplakin rod domain. Before deter-
mining the cleavage site, another site, LEID-1634, was
considered as a possible consensus sequence for caspase
6. This more conventional sequence is, however, located in
a coiled-coil region of the periplakin rod domain, possibly
preventing the access of the caspase. Peptide substrates
for caspases have been extensively tested (Talanian et al,
1997). Ac-YVAD-pNA was preferred by caspase 1 and
Ac-VDVAD-pNA by caspase 2, but these peptides were not
cleaved by caspase 6. In type I keratins, peptide sequences
VEMD and VEVD, and in lamins VEID and VEVD, are
cleaved by caspase 6 (see Caulin et al, 1997). Although the
caspase-recognition site in periplakin, TVAD, is closest to
that preferred by caspases 1 and 2, in vitro periplakin was
not cleaved by these caspases.
It is known that after induction of apoptosis, cytoskeletal
elements and cell adhesion structures become degraded
through the action of caspases. Plakin proteins plectin,
desmoplakin, and periplakin are all cleaved by caspases
but, surprisingly, different caspases preferentially cleave
each of these proteins (Stegh et al, 2000; Weiske et al, 2001;
Aho, 2004b). Whereas plectin and desmoplakin are cleaved
by multiple caspases, periplakin was cleaved only by ca-
spase 6 in vitro, which also cleaves the majority of IF pro-
teins. Thus, when cytoskeletal structures are reorganized
during development, growth, and tissue remodeling, peripl-
akin degradation can take place together with IF proteins,
whereas a different set of caspases is involved in the deg-
radation of other plakin proteins. It is worth noting that
specific binding of PKB/c-Akt to periplakin (van den Heuvel
et al, 2002) may protect periplakin from cleavage by ca-
spases in some circumstances, as the PKB/c-Akt is known
for its antiapoptotic function (Brazil et al, 2002; Le Gall et al,
2003).
Finally, periplakin has been characterized as one of five
plakin proteins targeted by autoantibodies in paraneoplastic
pemphigus (PNP) (Anhalt et al, 1990; Anhalt, 1997; Mahon-
ey et al, 1998). The etiology of this autoimmune disease is
not known. Clustering of intracellular molecules in the sur-
face blebs of apoptotic cells may expose the antigens and
their novel apoptotic fragments with non-tolerated struc-
tures to the immune system (Casciola-Rosen et al, 1994).
Defective clearance or reduced anti-inflammatory conse-
quences of apoptotic material has been suggested to pro-
vide a susceptibility factor to initiate a primary immune
response (Rosen and Casciola-Rosen, 1999). It remains to
be studied as to whether defects in the clearance of apo-
ptotic cells in general, and especially the defective elimina-
tion of periplakin cleavage products, play a role in the onset
of autoimmune response to plakin proteins in PNP.
Materials and Methods
Generation of cDNA constructs for bacterial expression and
protein puriﬁcation Full-length or fragments of human periplakin
(see Fig 1) and human vimentin and keratins 8, 18, 5, 14, 1, and
10 were cloned into pET-23 bacterial expression vector (Novagen,
Inc., Madison, Wisconsin) in-frame with C-terminal 6-His tag, ex-
pressed in bacteria and purified as described (Kalinin et al, 2004).
Proteins were resolved on 4%–12% Bis–Tris NuPAGE gels with
MOPS running buffer (Invitrogen, Carlsbad, California).
Dot-blot overlay assay IF proteins (1 mg each) were applied to
PVDF membrane using the 96-well Bio-Dot Microfiltration System
(BioRad Laboratories, Hercules, California). After blocking, the
membrane was incubated with the purified periplakin fragments at
5 mg per mL for 1 h at room temperature (RT). Bound periplakin
was detected using chicken anti-periplakin tail antibodies and
horseradish peroxidase (HRP)-conjugated anti-chicken secondary
antibodies (procedures were identical to the western protocol). The
equal loading of IF proteins was verified by Amido Black staining of
the membrane.
F-actin and IF co-sedimentation assays The Actin-Binding Pro-
tein Biochem Kit was purchased from Cytoskeleton (Denver, Colo-
rado) and F-actin was assembled according to the manufacturer’s
instructions. Typically, 1 mg of test protein was added to 5–10 mg of
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freshly assembled F-actin in 5 mM Tris-HCl, pH 8.0, 50 mM KCl,
1 mM MgCl2, 1 mM ATP, and 0.2 mM CaCl2. Samples were incu-
bated at RT for 20 min and ultracentrifuged for 30 min at 29 p.s.i.
(about 175,000  g) in a Beckman Airfuge (Beckman Coulter, Full-
erton, California). Supernatants (non-bound protein) and pellets
(cytoskeleton-bound protein) were analyzed by SDS-PAGE. To de-
termine the binding parameters, a range of test protein concen-
trations was used, and the amount of protein in the pellet and in the
supernatant was quantitated by densitometry of Coomassie Blue-
stained gels. Data were analyzed using GraphPad Prism software
(GraphPad Software, San Diego, California).
IF were assembled by step dialysis as described (Yamada et al,
2003), and binding experiments were carried out as described
above, but in 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 5 mM b-
mercaptoethanol (b-ME).
Cross-linking experiments Purified proteins at 100 mg per mL in
25 mM Triethanolamine-HCl, pH 7.8 were cross-linked with 2 mM
Bis[2-(sulfosuccinimidooxycarbonyloxy)ethyl]sulfone (Sulfo-BSO-
COES) (Pierce, Rockford, Illinois, USA) at room temperature for
30 min, followed by SDS-PAGE on 4%–12% Bis–Tris NuPAGE gels
with MOPS running buffer (Invitrogen). Protein bands were visu-
alized by Coomassie Blue staining.
Size-exclusion chromatography The apparent molecular mass
of recombinant proteins was estimated on Superdex 200 10 per
300 column (Amersham Biosciences, Piscataway, New Jersey)
calibrated with thyroglobulin (669 kDa), ferritin (440 kDa), catalase
(232 kDa), lactate dehydrogenase (140 kDa), bovine serum albumin
(66 kDa) (all from Amersham Biosciences), and chymotrypsinogen
(25 kDa) (Sigma, St Louis, MO, USA). The retention factor (KD) was
calculated as KD¼ (VeVo)/(VtVo), where Ve is the protein elution
volume, Vo is the column void volume, and Vt is the total column
bed volume.
Expression of tagged periplakin in MDCK cells The full-length
periplakin cDNA in pcDNA3.1 (Aho, 2004a) was tagged with the N-
terminal FLAG-epitope by inserting a synthetic double-stranded
oligonucleotide with the EcoRI-compatible ends into the partially
EcoRI-digested periplakin-pcDNA3.1 plasmid. The FLAG-peripl-
akin cDNA was released with HindIII-NotI digestion and ligated into
the HindIII-NotI digested pCEP4t. A C-terminal HA-tag was insert-
ed by ligation of a double-stranded synthetic oligonucleotide with
NotI-compatible ends into the NotI-digested FLAG-periplakin-
pCEP4t. The pCEP4 (Invitrogen) had been modified to drive the
expression of the transgene from a minimal CMV promoter under
the control of seven repeats of tet response element, resulting in
the expression vector pCEP4t. The vector contains the EBNA-1
gene for episomal autonomous replication in mammalian cells and
a hygromycin gene for the selection of transfected cells. Compe-
tent Escherichia coli cells, JM109 (Promega, Madison, Wisconsin)
or XL-1 Blue (Stratagene, La Jolla, California), were used for trans-
formation, and plasmids were purified using the Wizard Miniprep
Kit (Promega). Purified plasmids were sequenced to confirm the in-
frame ligation of the inserts.
The Tet-Off MDCK cell line was purchased from Clontech (San
Diego, California) and grown according to the provider’s instruc-
tions. For the transfections, cells were plated on the 60-mm plates,
and the FuGENE 6 Transfection Reagent (Roche Diagnostics, In-
dianapolis, Idiana) was used in the ratio of 1 mg of DNA to 3 mL of
transfection reagent, following the manufacturer’s instructions.
Doxycycline was included in the transfection medium, and 24 h
after transfection, selection was started with hygromycin. Cultures
were trypsinized and replated before reaching confluency, usually
every 3–4 d. After three to five passages, no adherent cells re-
mained in the untransfected control cultures. For the induction of
the transgene expression, cells were trypsinized and plated with-
out doxycycline, allowed to grow to 70% confluency, trypsinized
again, and replated on 60-mm tissue culture plates before har-
vesting for the western blotting, and replated into the 4-well cham-
ber slides for indirect IIF.
Induction of apoptosis MDCK cells expressing tagged periplakin
were plated on the 60-mm tissue culture plates and grown to 80%
confluency. Apoptosis was induced by 1 mM STS (Sigma) applied
from 1000  stock in dimethyl sulphoxide (DMSO). A cell-perme-
able caspase inhibitor zVAD-fmk (Biomol) was applied to the cells
in 40 mM concentration from the 500  stock 30 min prior to the
STS addition. A control culture was treated with an equal volume of
DMSO.
IIF microscopy For the IIF, the cultured cells on the chamber
slides were fixed with methanol for 5–10 min and, after two washes
with PBS, were further permeabilized with 0.1% Triton X-100 in
PBS for 5 min at RT, followed by three washes with PBS. Blocking
was carried out with 1% bovine serum albumin (BSA) in PBS for 1 h
at RT, followed by primary antibody incubation at 81C overnight.
Slides were washed three times with PBS, each time for 5 min,
followed by the secondary antibody incubation at RT for 1 h. After
three washes with PBS, slides were mounted and studied under a
fluorescent microscope (Axioskop, Carl Zeiss, Inc., Thornwood,
New York). The images were stored with ImagePro Plus 4.0 im-
aging software (Media Cybernetics, Silver Spring, Maryland) and
processed with Photoshop 5.0 (Adobe Systems Inc., San Jose,
California) and Canvas 7 (Deneba Software, Miami, Forida).
Cell extraction and western analysis Adherent cells on the 60-
mm tissue culture plates were briefly washed and extracted with
150 mL of radioimmunoprecipitation-buffer: 50 mM Tris-HCl, pH
7.5; 150 mM NaCl; 1% Nonidet P-40 (NP-40); 0.5% deoxycholate;
0.1% SDS; protease inhibitor Complete (Roche Diagnostics), one
tablet dissolved into 10 mL of buffer. After extraction and sonicat-
ion, cell lysate was separated from the insoluble pellet through
centrifugation for 15 min at 14,000  g at 81C. The soluble fraction
was mixed with 2  SDS-Laemmli sample buffer (Bio-Rad) sup-
plemented with b-ME (sample buffer (SB)). Floating cells from the
culture medium were collected through a brief centrifugation and
dissolved into 150 mL of SB. All samples were heated for 15 min at
961C before loading on the PAGE.
For western analysis, 10-mL aliquots of cell lysates were sep-
arated either on SDS–5% PAGE or on the 4%–20% gradient PAGE
and transferred onto PVDF membranes (PerkinElmer Life Scienc-
es, Boston, Massachussets). The membranes were blocked for 1 h
at RT in PBS, 1% BSA, and 5% non-fat dried milk. After the pri-
mary antibody incubation in 1% BSA in PBS overnight at 81C, the
membranes were washed four times, 10 min each wash, in 0.5%
Tween 20 in Tris-buffered saline, followed by incubations for 1 h at
RTwith the secondary antibody, and then washed again. The signal
was developed using Western Lightning Chemiluminescence Re-
agent Plus (PerkinElmer Life Sciences).
In vitro cleavage of periplakin by recombinant caspases Re-
combinant human caspases 1–10 were purchased from Biomol. To
examine periplakin as a substrate for caspases, 10 mg of MDCK
cell lysate was diluted into 40 mL of the caspase assay buffer (50
mM HEPES, pH 7.4; 100 mM NaCl; 10 mM dithiothreitol; 1 mM
EDTA; 0.1% CHAPS; 10% glycerol) containing 2 U per mL of the
recombinant caspases 1–10. After incubation for 18 h at 301C, the
reaction was stopped by boiling in reducing Laemmli sample buffer
(Bio-Rad), and the proteins were separated through SDS-PAGE.
For caspase 6 cleavage site determination, 0.5 mg of recom-
binant protein Pr231t was incubated with 1500 U of the recom-
binant caspase 6 for 18 h at 301C in 1 mL of the caspase buffer. A
10-mL aliquot was resolved on SDS-gel and transferred to se-
quence-grade PVDF membrane by western blotting. Proteins on
the membrane were stained with 0.1% Amido Black (Sigma) in
25% ethanol, 10% acetic acid for 1 min, and background was
removed by two 10-min washes in 50% ethanol, 2% acetic acid.
The membrane was air-dried, the band corresponding to the C-
terminal fragment was cut out, and its N-terminal amino acid se-
quence was determined on a Beckman 6300 analyzer (Beckman
Coulter). The C-terminal fragment of periplakin was purified from
the remainder of caspase 6-cleaved sample on Ni–NTA beads
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(Qiagen, Valencia, California) according to the manufacturer’s in-
structions and used for the overlay and co-sedimentation assays.
Primary and secondary antibodies The following commercially
available antibodies were used: mouse monoclonal anti-FLAG M2
(1:3000; Stratagene), rabbit HA-tag (1:3000; Covance, Richmond,
California), mouse monoclonal HA-tag (1;10,000; Covance), and
mouse monoclonal anti-actin antibody clone C4 (0.2 pg per mL;
Boehringer/Roche Diagnostics).
The polyclonal chicken antibody against periplakin C-terminus
was produced by Aves Labs, Inc. (Tigard, Oregon). Purified re-
combinant periplakin tail domain (periplakin aa 1638–1756, without
the His tag) was used for immunization. The antibody was affinity
purified and used at 1 mg per mL. The GST–periplakin fusion pro-
tein (periplakin aa 1548–1756) was used to immunize mice, and a
hybridoma cell line-producing monoclonal antibody PPL-Y88 rec-
ognizing periplakin aa 1548–1583 was selected (Aho, 2004a).
HRP-conjugated goat anti-chicken IgY was purchased from
Aves Labs, Inc., and used at 1:25,000 dilution. HRP-conjugated
secondary antibodies against mouse, rabbit, and goat IgG were
purchased from Jackson ImmunoResearch Laboratories (West
Grove, Pennsylvania), and used for the western blotting in 1:25,000
dilution. Species-specific secondary antibodies, conjugated with
Texas Red and fluorescein isothiocyanate, were also purchased
from Jackson ImmunoResearch Laboratories, and used for IIF in
1:500 dilution in PBS–1% BSA. Nuclei were visualized with DAPI,
which was included in the secondary antibody incubation.
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